FY2024 Earnings Estimate for VIRX Issued By Leerink Partnrs

Viracta Therapeutics, Inc. (NASDAQ:VIRX) – Stock analysts at Leerink Partnrs lowered their FY2024 EPS estimates for shares of Viracta Therapeutics in a report issued on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now forecasts that the company will earn ($0.80) per share for the year, down from their previous estimate of ($0.69). The consensus estimate for Viracta Therapeutics’ current full-year earnings is ($0.80) per share. Leerink Partnrs also issued estimates for Viracta Therapeutics’ Q4 2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.36) EPS and FY2026 earnings at ($0.40) EPS.

Several other brokerages also recently commented on VIRX. Leerink Partners downgraded shares of Viracta Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $5.00 to $3.00 in a research report on Friday, August 16th. Royal Bank of Canada cut their target price on shares of Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th.

Viracta Therapeutics Stock Performance

Shares of NASDAQ:VIRX opened at $0.15 on Monday. The company has a market cap of $5.96 million, a PE ratio of -0.14 and a beta of 0.72. Viracta Therapeutics has a 52 week low of $0.13 and a 52 week high of $1.31. The firm has a 50 day simple moving average of $0.22 and a 200 day simple moving average of $0.42.

Institutional Investors Weigh In On Viracta Therapeutics

An institutional investor recently bought a new position in Viracta Therapeutics stock. Stonepine Capital Management LLC purchased a new stake in shares of Viracta Therapeutics, Inc. (NASDAQ:VIRX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned approximately 1.27% of Viracta Therapeutics at the end of the most recent quarter. 31.37% of the stock is owned by hedge funds and other institutional investors.

About Viracta Therapeutics

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.